Managing heart failure in diabetics with dual acting sotagliflozin—A review

Heart failure (HF) is a chronic disorder that decreases heart function and causes a person to be less tolerant to exercise, have a lower quality of life, and prone to death. Novel therapeutic strategies are still needed despite improvements in HF management. Sotagliflozin is a promising medication for the treatment of HF, which is a dual sodium-glucose cotransporter 1 as well as 2 (SGLT1 and SGLT2) inhibitor. The purpose of this in-depth study is to assess sotagliflozin's effectiveness and safety in the treatment of HF. The effects of sotagliflozin on different facets of HF pathophysiology, such as blood flow, myocardial remodeling, and neurohormonal stimulation, are discussed in preclinical and clinical investigations. Sotagliflozin has been shown to be effective in lowering the risk of HF hospitalization and heart attack in patients with HF with either type 2 diabetic mellitus (T2DM) and chronic kidney disease (CKD), according to numerous randomized trials, including the most recent SOLOIST-WHF or SCORED trials. Sotagliflozin's simultaneous inhibition of SGLT1 along with SGLT2 creates a special pharmacological profile that addresses both the metabolic as well as non-metabolic problems seen in HF. This review provides a comprehensive summary of various aspects related to sotagliflozin and heart failure, including the pathophysiology in heart failure, US-FDA approved treatment for HF, mechanism of action, pharmacokinetic, pharmacodynamics data of sotagliflozin, reported adverse drug reactions (ADRs), and ongoing clinical trials.